What You Will Learn

Clinical study protocols are vital to drug development, and when carefully designed, deliver practical clinical care and answer critical research questions. This balance of science and medicine provides the foundation for advancing the next big idea from the laboratory to the pharmacy. Still, this achievement is dependent on each drug’s ability to demonstrate safety and effectiveness during the phases of a clinical trial. Explore with us as we discuss different protocol writing and study design approaches, ensuring protocols are designed to meet both the patients’ and Sponsor’s needs, and maintaining compliance with the International Council for Harmonisation requirements.

Attendees will learn about:

  • Key differences in clinical study design among phases of development
  • Statistical methods for interpreting analyses
  • New efficiencies in clinical study design strategy -Benefits of using the master or subprotocol
  • Benefits of tech-enabled templates
Our Experts
Aaron Burr
Senior Medical Writer, Regulatory and Medical Writing
Tasnim Hoda
Manager, Regulatory and Medical Writing
Hung Lam
Principal Biostatistician, Biometrics
Victoria Murray
Technical Manager, Regulatory and Medical Writing

Register Now

Suggested For You

webinar

September 26th, 2024

Regulatory Pathways for Nonprescription Drugs: A Deep Dive into OTC Monograph Reform and FDA Guidance

webinar

September 12th, 2024

No Stone Unturned: Optimizing the Use of Expedited Pathways and Oncology Center of Excellence Programs to Optimize Drug Development in Oncology

webinar

March 26th, 2024

Type II Drug Master Files for Early-Stage, Small Molecule, Drug Development: Regulatory Management, Quality Considerations, and eCTD Submission

webinar

January 17th, 2024

How to Create Fit-For-Purpose Clinical Study Reports for Successful Submissions

regulatory intelligence

January 17th, 2025

New FDA Protocol Deviation Guidance:  Planning for the Things That Don’t Go According to Plan

regulatory intelligence

August 26th, 2024

Oncology Programs at the FDA

regulatory intelligence

August 26th, 2024

Three Key Reflections on the Recent Donanemab Approval

regulatory intelligence

August 9th, 2024

FDA Updates 2024 Language Access Plan

regulatory intelligence

July 26th, 2024

Key Decision Points for Recent Oncology Approvals

perspectives

July 16th, 2024

Key Steps to Successful CMC Authoring of IND and IMPD Submissions

perspectives

June 21st, 2024

Peer-Reviewed Journal Articles: The Crucial Role of Publication in the Pharmaceutical Industry

perspectives

April 19th, 2024

The Emerging Role of Artificial Intelligence (AI) in Global Medical Writing